Phase 2Not yet recruiting
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
ROSETTA Lung-220: A Phase 2, Open-Label, Multicenter, Multi-Arm Platform Study Evaluating Pumitamig and Other Novel Neoadjuvant Regimens in Participants With Resectable, Early-Stage (IIA to IIIB) Non-Small Cell Lung Cancer
- Sponsor
- Bristol-Myers Squibb (Industry)
- Enrolment
- 80 planned
- Conditions
- Early-Stage Non-Small Cell Lung Cancer
- Interventions
- Pumitamig; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Ages
- adults, older adults
- Registry
- NCT07871214, CTIS2026-527590-11-00
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer
Primary outcomes
- Achievement of pathologic complete response (pCR) by blinded independent pathology review (BIPR)
History
Primary completion expected
Expected to start
Registered